Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21

Cancer Research

Volumn 67, Issue 18, 2007, Pages 8477-8485

  Klampfer, Lidija ^a   Huang, Jie ^a   Shirasawa, Senji ^b   Sasazuki, Takehiko ^b   Augenlicht, Leonard ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APICIDIN; BUTYRIC ACID; CAMPTOTHECIN; CASPASE 3; CASPASE 7; CASPASE 9; DOCETAXEL; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROPYL THIOGALACTOSIDE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KRASV12; PROTEIN P21; RAS PROTEIN; SMALL INTERFERING RNA; STAT1 PROTEIN; SYNAPTOTAGMIN I; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; HYPERACETYLATION; INTESTINE EPITHELIUM CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BUTYRATES; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, RAS; HCT116 CELLS; HISTONE DEACETYLASES; HUMANS; MUTATION; RAS PROTEINS; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 34548789152     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0210     Document Type: Article

References (45)

1. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13-8.
2. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
3. Klampfer L, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. Oncogenic Ras promotes butyrate-induced apoptosis through inhibition of gelsolin expression. J Biol Chem 2004;279:36680-8.
4. Bivona TG, Quatela SE, Bodemann BO, et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell 2006;21:481-93.
5. Klampfer L, Huang J, Corner G, et al. Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression. J Biol Chem 2003;278:46278-87.
6. Brem R, Certa U, Neeb M, Nair AP, Moroni C. Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model. Oncogene 2001;20:2854-8.
7. Krasilnikov M, Ivanov VN, Dong J, Ronai Z. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 2003;22:4092-101.
8. Bowman T, Jove R. STAT proteins and cancer. Cancer Control 1999;6:615-9.
9. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
10. Kulaeva OI, Draghici S, Tang L, et al. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 2003;22:4118-27.
11. Missiaglia E, Donadelli M, Palmieri M, et al. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 2005;24:199-211.
12. Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR. Complex roles of Stat1 in regulating gene expression. Oncogene 2000;19:2619-27.
13. Chin YE, Kitagawa M, Su WC, et al. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996;272:719-22.
14. Chen B, He L, Savell VH, Jenkins JJ, Parham DM. Inhibition of the interferon-γ/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res 2000;60:3290-8.
15. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon g-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61.
16. Yang WC, Mathew J, Velcich A, et al. Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res 2001;61:565-9.
17. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-8.
18. Lee TH, Klampfer L, Shows TB, Vilcek J. Transcriptional regulation of TSG6, a tumor necrosis factor- and interleukin-1-inducible primary response gene coding for a secreted hyaluronan-binding protein. J Biol Chem 1993;268:6154-60.
19. Sowa Y, Orita T, Minamikawa S, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997;241:142-50.
20. Zamai L, Falcieri E, Marhefka G, Vitale M. Supravital exposure to propidium iodide identifies apoptotic cells in the absence of nucleosomal DNA fragmentation. Cytometry 1996;23:303-11.
21. Sheng H, Shao J, Dubois RN. K-Ras-mediated increase in cyclooxygenase 2mR NA stability involves activation of the protein kinase B1. Cancer Res 2001;61:2670-5.
22. Heerdt BG, Houston MA, Wilson AJ, Augenlicht LH. The intrinsic mitochondrial membrane potential (Dcm) is associated with steady-state mitochondrial activity and the extent to which colonic epithelial cells undergo butyrate-mediated growth arrest and apoptosis. Cancer Res 2003;63:6311-9.
23. Klampfer L, Huang J, Swaby LA, Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 2004;279:30358-68.
24. Mahyar-Roemer M, Roemer K. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 2001;20:3387-98.
25. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 1998;95:6791-6.
26. Coccia EM, Del Russo N, Stellacci E, et al. Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2. Oncogene 1999;18:2129-37.
27. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003;133:2485-93S.
28. Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 2002;99:2995-3000.
29. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-κB activation and cellular proteasome activity. J Biol Chem 2001;276:44641-6.
30. Inan MS, Rasoulpour RJ, Yin L, et al. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology 2000;118:724-34.
31. Klampfer L, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. Inhibition of interferon γ signaling by the short chain fatty acid butyrate. Mol Cancer Res 2003;1:855-62.
32. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000;60:4561-72.
33. Insinga A, Minucci S, Pelicci PG. Mechanisms of selective anticancer action of histone deacetylase inhibitors. Cell Cycle 2005;4:741-3.
34. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-6.
35. Agrawal S, Agarwal ML, Chatterjee-Kishore M, Stark GR, Chisolm GM. Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol-induced apoptosis. Mol Cell Biol 2002;22:1981-92.
36. Stehr W, Bernal NP, Bernabe KQ, Erwin CR, Warner BW. Absent STAT-1 expression perturbs adaptation and apoptosis after massive intestinal resection. J Pediatr Surg 2006;41:713-8.
37. Choudhary S, Wang HC. Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells. Mol Cancer Ther 2007;6:1099-111.
38. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997;278:1630-2.
39. Sowa Y, Orita T, Hiranabe-Minamikawa S, et al. Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann N Y Acad Sci 1999;886:195-9.
40. Look DC, Pelletier MR, Tidwell RM, Roswit WT, Holtzman MJ. Stat1 depends on transcriptional synergy with Sp1. J Biol Chem 1995;270:30264-7.
41. Arango D, Mariadason JM, Wilson AJ, et al. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003;89:1757-65.
42. Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
43. Khodarev NN, Beckett M, Labay E, et al. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A 2004;101:1714-9.
44. Patterson SG, Wei S, Chen X, et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006;25:6113-22.
45. Kramer OH, Baus D, Knauer SK, et al. Acetylation of Stat1 modulates NF-κB activity. Genes Dev 2006;20:473-85.